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Eicosanoids are important mediators of fever, pain, and
inflammation that modulate cell signaling during acute and
chronic disease. We show by using lipidomics that thrombin-
activated humanplatelets generate a new type of eicosanoid that
both stimulates and primes human neutrophil integrin (Mac-1)
expression, in response to formylmethionylleucylphenylala-
nine. Detailed characterization proposes a dioxolane structure,
8-hydroxy-9,11-dioxolane eicosatetraenoic acid (dioxolane A3,
DXA3). The lipid is generated in nanogramamounts by platelets
from endogenous arachidonate during physiological activation,
with inhibition by aspirin in vitro or in vivo, implicating
cyclooxygenase-1 (COX). Pharmacological and genetic studies
on human/murine platelets revealed that DXA3 formation
requires protease-activated receptors 1 and 4, cytosolic phos-
pholipase A2 (cPLA2), Src tyrosine kinases, p38 MAPK, phos-
pholipase C, and intracellular calcium. From data generated by
purified COX isoforms and chemical oxidation, we propose that
DXA3 is generated by release of an intermediate from the active
site followed by oxygenation at C8. In summary, a new neutro-
phil-activating platelet-derived lipid generated by COX-1 is
presented that can activate or prime human neutrophils, sug-
gesting a role in innate immunity and acute inflammation.
Emerging evidence indicates that platelets influence innate
immunity during acute infection and injury through their inter-
actions with leukocytes (1–3). Platelets generate soluble
lipid-signaling mediators that include eicosanoids such as
thromboxaneA2 (TXA2)4 and 12-hydroxyeicosatetraenoic acid
(12-HETE) and small amounts of the prostaglandins (PGs)
PGE2 and D2. Currently the effects of platelet-derived lipids on
leukocytes are not fully known. In this study, we sought to dis-
cover whether platelets release leukocyte-regulating lipids
using a lipidomic approach. Analogous methodologies have
recently been used for discovery of lipids in diabetes, cardiovas-
cular disease, and hemostasis (4–6).
Herein, we show that thrombin-activated human platelets
generate a novel eicosanoid from endogenous substrate, pro-
posed to be a dioxolane (DX), that elevates Mac-1 (CD11b/
CD18) on neutrophils at nanomolar concentrations. We also
present the detailed cellular and enzymatic mechanisms of for-
mation along with characterization of its proposed covalent
structure and established a quantitative assay. These data dem-
onstrate a new platelet-derived leukocyte-activating eicosanoid
and the first DX lipid to originate from mammalian cells, sug-
gesting a novel mechanism for promoting neutrophil activities
in the early stage of tissue damage/wounding responses.
Experimental Procedures
Materials
Lipids and lipid standards were purchased fromAvanti Polar
Lipids (Alabaster, AL) or Cayman Chemical (Ann Arbor, MI).
Deuterated standards are as follows: arachidonic acid-d8,
5Z,8Z,11Z,14Z-eicosatetraenoic-5,6,8,6:54 PM 5/12/20169,
11,12,14,15-d8 acid, 99% deuterated forms; PGE2-d4, 9-oxo-
11,15S-dihydroxy-prosta-5Z,13E-dien-1-oic-3,3,4,4-d4 acid,
99% deuterated forms; and PGD2-d4, 9,15S-dihydroxy-11-
oxo-prosta-5Z,13E-dien-1-oic-3,3,4,4-d4 acid, 99% deuter-
ated forms. HPLC grade solvents were from Thermo Fisher
Scientific (Hemel Hempstead, Hertfordshire, UK). PAR-1 and
PAR-4 agonists were from Tocris Biosciences (Bristol, UK).
COX-1 inhibitor (Sc-560) was from Cayman Chemical. Plate-
let signaling inhibitors (PP2, oleyloxyethylphosphocholine
(OOEPC), bromoenol lactone, cytosolic phospholipase A2
(cPLA2) inhibitor (N-{(2S,4R)-4-(biphenyl-2-yl-methyl-
isobutyl-amino)-1-[2-(2,4-difluorobenzoyl)-benzoyl]-pyrroli-
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din-2-ylmethyl}-3-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)-
phenyl]acrylamide, HCl), U73112, wortmannin, and p38
mitogen-activated protein kinase (MAPK) inhibitor were from
Calbiochem (United Kingdom). Anti-human CD11b-Alexa
Fluor 647 was from eBioscience. All other reagents were from
Sigma unless otherwise stated. [14C]Arachidonic acid was from
PerkinElmer Life Sciences; ovine COX-1 was from Cayman
Chemical or purified as described (7, 8). Recombinant
COX-2 was generated as described (9). N-Methyl benzohy-
droxamic acid (NMBHA) and 2,2-azobis(4-methoxy-2,4,di-
methyl valeronitrile) were kind gifts from Ned Porter (Van-
derbilt University).
Isolation of Human andMurine Platelets
Human blood donations were approved by the Cardiff Uni-
versity School of Medicine Ethics Committee, were with
informed consent (SMREC 12/37 and SMREC 12/10), and
according to the Declaration of Helsinki. For cPLA2-deficient
samples, samples were approved by St Thomas’s Hospital
Research Ethics Committee, reference 07/Q0702/24: patient
samples; South East NHS Research Ethics Committee. For
studies on isolated platelets, whole blood was collected from
healthy volunteers free from non-steroidal anti-inflammatory
drugs for at least 14 days and added to acid/citrate/dextrose
(ACD; 85 mmol/liter trisodium citrate, 65 mmol/liter citric
acid, 100 mmol/liter glucose) (blood/ACD, 8.1:1.9, v/v) then
centrifuged at 250 g for 10min at room temperature. Platelet-
rich plasmawas collected and centrifuged at 900 g for 10min,
and the pellet was resuspended in Tyrode’s buffer (134 mmol/
liter NaCl, 12 mmol/liter NaHCO3, 2.9 mmol/liter KCl, 0.34
mmol/liter Na2HPO4, 1.0 mmol/liter MgCl2,10 mmol/liter
Hepes, 5mmol/liter glucose, pH 7.4) containingACD (9:1, v/v).
Platelets were centrifuged at 800 g for 10min and then resus-
pended in Tyrode’s buffer at 2 108ml1. Platelets were acti-
vated at 37 °C in the presence of 1 mmol/liter CaCl2 for varying
times, with 0.2 unitsml1 thrombin, 10 g/ml collagen, 10
mol/liter A23187, 20 mol/liter TFLLR-NH2, or 150 mol/
liter AY-NH2 before lipid extraction as below. Experiments
involving signaling inhibitors (1 mmol/liter aspirin, 1 mol/
liter SC-560, 10 mol/liter indomethacin, 2 mol/liter oley-
loxyethylphosphocholine, 50 nmol/liter bromoenol lactone, 50
nmol/liter cPLA2i, 75 M thimerosal, 1 mM EGTA, 10 M 1,2-
bis(2-aminophenoxy)ethane-N,N,N,N-tetraacetic acid tet-
rakis(acetoxymethyl ester), 100 nMwortmannin, 100 nmol/liter
Gö 6850, 50 mol/liter PP2, 100 nmol/liter p38 MAPK inhibi-
tor, 50 M picotamide, 1–10 mM iodoacetate, and 5 M
U-73122) included a 10-min preincubation at room tempera-
ture. In some experiments, calcium was omitted from buffers.
For separation of cells from microparticles, platelets were cen-
trifuged at 970 g for 5min, and the supernatantswere re-spun
at 16,060  g for 5 min. For aspirin supplementation, blood
samples were first obtained following a 14-day nonsteroidal
anti-inflammatory drug-free period for baseline determina-
tions of eicosanoids. Subjects were administered 75 mg/day
aspirin for 7 days, and they then provided a second blood sam-
ple. Platelets were isolated and activated in vitro using 0.2
unit/ml thrombin, as described above, and then lipids were
extracted as described below. Exclusion criteria was a known
sensitivity to aspirin. For studies on isolated murine platelets,
whole blood was collected using cardiac puncture (mice were
28 weeks old) into 150 l of ACD (85 mmol/liter trisodium
citrate, 71 mmol/liter citric acid, 100 mmol/liter glucose). 150
l of 3.8% sodium citrate and 300 l of Tyrode’s buffer (145
mmol/literNaCl, 12mmol/literNaHCO3, 2.95mmol/liter KCl,
1.0 mmol/liter MgCl2,10 mmol/liter Hepes, 5 mmol/liter glu-
cose, pH 7.35) were added, and the blood was centrifuged at
150  g for 5 min at room temperature. Platelet-rich plasma
was collected, and 400 l of Tyrode’s buffer was added to the
red cells and centrifuged again at 150  g for 5 min at room
temperature. Platelet-rich plasma was combined and centri-
fuged at 530 g for 5 min at room temperature. Platelets were
resuspended in Tyrode’s buffer at 2  108 ml1. All animal
experiments were performed in accordance with the 1986
United Kingdom Home Office Animals Act (Scientific Proce-
dures). 12/15-LOX knock-out mice were generated as
described previously (10), and wild-type male C57BL/6 mice
(25–30 g) from Charles River, UK, were kept in constant tem-
perature cages (20–22 °C) and given free access to water and
standard chow.
Isolation and Activation of HumanNeutrophils
Human neutrophils were isolated from 20 ml of citrate anti-
coagulated whole blood and resuspended in Krebs buffer.
Briefly, bloodwasmixed 1:3with 2% trisodiumcitrate (w/v) and
HetaSep (Stemcell Technologies) and allowed to sediment for
45 min at 20 °C. The upper plasma layer was recovered and
underlaid with ice-cold LymphoprepTM (2:1 for plasma/Lym-
phoprepTM) and centrifuged at 800 g for 20 min at 4 °C. The
pellet was resuspended in ice-cold PBS and 0.4% sodium trici-
trate (w/v) and centrifuged at 400  g for 5 min at 4 °C. Con-
taminating erythrocytes were removed using up to three cycles
of hypotonic lysis. Finally, cells were resuspended in a small
volume of Krebs buffer (100 mmol/liter NaCl, 50 mmol/liter
Hepes, 5 mmol/liter KCl, 1 mmol/liter MgCl2, 1 mmol/liter
NaH2PO4, 1 mmol/liter CaCl2, and 2 mmol/liter D-glucose, pH
7.4), counted, and kept on ice. Neutrophils were diluted to 2
106 cells/ml and incubated with or without DXA3 for 10 min at
37 °C. In some experiments, 10 M fMLP was then added, and
neutrophils were incubated for a further 10 min at 37 °C. Cells
were blocked using 5% mouse serum in PBS (containing 0.5%
BSA, 5 mmol/liter EDTA, and 2 mmol/liter sodium azide) for
1 h on ice and centrifuged at 320  g for 5 min at 4 °C. Anti-
humanCD11b-Alexa Fluor 647 (0.0625g, eBioscience) or iso-
type control were added and incubated for 30 min on ice. Neu-
trophils were washed twice with ice-cold PBS (containing 0.5%
BSA, 5 mmol/liter EDTA, and 2 mmol/liter sodium azide) and
dissolved in the same buffer for flow cytometric analysis. Neu-
trophils were analyzed on a cyan ADP flow cytometer (Beck-
man Instruments) and identified by forward and side scatter
and Alexa Fluor 647. DXA3 used for these experiments was
purified fromCOX-1 incubations.Other lipidswere not detect-
able in these preparations using MS.
Culturing and Activation of RAW264 Cells
RAW 264 cells were cultured in DMEM (10% FBS, 1 peni-
cillin/streptomycin) at 37 °C and 5% CO2.
ANew Bioactive Eicosanoid Generated by Human Platelets
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To determine PG synthesis, cells were incubated in serum-
free DMEM (with 1 penicillin/streptomycin), and the cells
were incubated for 1 h at 37 °C, 5%CO2.Where used, 200 ng/ml
LPSwas added, and cells were incubated for 24 h. Cells (8 106
ml1) were treated with 10 M ionophore at 37 °C for 10 min,
and lipids were extracted and analyzed as described below.
Isolation of Human Serum
Whole blood fromhealthy volunteers was clotted at 37 °C for
15min in glass and centrifuged (1500 rpm, 10min, 4 °C). Serum
was re-spun (2900 rpm, 10min, 4 °C), and 3 volumes ofMeOH/
water (20:80 v/v) were added. Protein precipitates were spun
down (13,000 rpm, 10 min, 4 °C), and supernatants were
applied to preconditionedWatersC18 Sep-Pak columns. These
were washed with 10 ml of water, 6 ml of hexane, and the eico-
sanoids were then eluted using 7 ml of methyl formate into
tubes containing 6 l of MeOH/glycerol (70:30 v/v) (11). Lipid
were redissolved in methanol, chilled (80 °C, 60 min), and
re-spun (13,000 rpm, 10 min, 4 °C) before LC/MS/MS analysis
for DXA3.
Lipid Extraction
Lipids were extracted by adding a solvent mixture (1 mol/
liter acetic acid, isopropyl alcohol, hexane (2:20:30, v/v/v)) to
the sample at a ratio of 2.5 ml to 1 ml of sample, vortexing, and
then adding 2.5 ml of hexane (12). Where quantitation was
required, 5–10 ng of PGE2-d4, PGD2-d4, and 12-HETE-d8 were
added to the samples before extraction, as internal standards.
After vortexing and centrifugation, lipids were recovered in the
upper hexane layer. The samples were then re-extracted by
addition of an equal volume of hexane. The combined hexane
layers were dried and analyzed for DXA3 using LC/MS/MS as
below.
Generation of DXA3 through Oxidation of 11-HPETE or by
Purified or Recombinant COX Isoforms
Arachidonic acid was oxidized using N-methylbenzhy-
droxamic acid (NMBHA) and 2,2-azobis(4-methoxy-2,4-dim-
ethylvaleronitrile) (MeOAMVN) as detailed below. To a 6.5M
arachidonic acid solution in chlorobenzene, 3.5 eq of NMBHA
and 0.1 eq of MeOAMVN were added, and the mixture was
stirred at 37 °C for 5 h under O2. After drying under N2, the
sample was dissolved in methanol and stored at 80 °C until
purification. Isolation of positional isomers used a Spherisorb
ODS2 column (5m, 150 4.6mm;Waters) with a gradient of
50–90% solvent B (acetonitrile, 0.1% formic acid) in solvent A
(water, 0.1% formic acid) for 60 min, 90% solvent B for 4.5 min,
and then re-equilibrating to 50% solvent B over 9.5 min with a
flow rate 1mlmin1. Elution wasmonitored at 205 nm (unoxi-
dized lipid) and 235 nm (HPETE). Fractions were collected and
positional isomers identified using MS/MS transitions for the
free HPETEs as follows: m/z 317.2 3 115.1 (5-HPETE); m/z
317.23 155.1 (8-HPETE);m/z 317.23 151.1 (9-HPETE);m/z
317.2 3 167.1 (11-HPETE); m/z 317.2 3 179.1 (12-HPETE);
andm/z 317.23 219.1 (15-HPETE). Next, purified 11-HPETE
was oxidized using 0.1 eq of MeOAMVN in 5 ml of chloroben-
zene by stirring at 37 °C for 5 h under O2, and the hydroperox-
ides were then reduced to corresponding hydroxides using tin
chloride (SnCl2). Lipids were extracted using the hexane/iso-
propyl alcohol extraction method, as described earlier.
Apo-COX-1 was stored in 80 mM Tris, pH 7.8, at80 °C. In
some experiments, a commercial preparation was used (Cay-
man Chemical). Wild-type murine COX-2 (recombinant) was
at 10.61 mgml1. For heme reconstitution, apo-COX-1 or -2
(35 g) was preincubated on ice for 20 min with 2 molar equiv-
alents of hematin in phosphate buffer (100mMpotassiumphos-
phate buffer, pH 7.4). Then, 3.5g of the reconstituted enzyme
was added to 1 ml of phosphate buffer and 500 mol/liter phe-
nol and incubated for 3 min at 37 °C in the presence of 150 M
arachidonate (AA or AA-d8). Where [14C]AA was used, 9.8 g
of enzyme was incubated with 70 M AA (259 kBq). In some
experiments, wild-type COX-2 was compared with active site
mutants (V349A and W387F). The reaction was stopped by
using ice-cold lipid extraction solvent and immediate extrac-
tion of lipids after addition of 5 ng each of PGE2-d4 and
PGD2-d4 as internal standards, when required. In some exper-
iments, 10 M diethylenetriaminepentaacetic acid was added
just before holo-COX-1. DXA3 was analyzed using reverse
phase LC/MS/MS as described below.
In some experiments, AA was replaced with 1-stearoyl-2-
arachidonyl-phosphatidylethanolamine. Free and esterified
DXAs3were analyzed using reverse phase LC/MS/MS as below.
Reversed Phase LC/MS/MS and LC/MS3 of DXA3 and Platelet
Eicosanoids
Several different LC separations were used on a 4000Q-Trap
platform. For high resolution mass analysis and fragmentation
of free DXA3, a reversed-phase UPLC Fourier Transform MS
method was used (Thermo Scientific Orbitrap Elite) using a
SpherisorbODS2 column (5m, 150 4.6mm;Waters) with a
flow rate of 1 mlmin1. Solvent B was increased from 20 to
42.5% over 50 min, then increased to 90% over 10.5 min, held
for 4 min, and then returned to 20% over 1 min. Equilibration
time between runs was 4.5 min. Analysis was performed using
heated ESI in negative ion mode at sheath, auxiliary and sweep
gas flows of 70, 20, and 0, and capillary and source heater tem-
peratures at 300 and 350 °C, respectively. LC/MS of parent ions
was monitored using accurate mass in Fourier MS mode. Neg-
ative MS/MS spectra were acquired using higher energy colli-
sion-induceddissociation.Data-dependentMS3 ofm/z 351was
carried out in ion trap-MS mode on the LTQ ion trap.
For MS/MS of m/z 351 or m/z 359, collision-induced disso-
ciation (CID) was used with a resolving power of 30,000 in neg-
ative FTMSmode. Data-dependent MS3 ofm/z 351 orm/z 359
from DXA3-d8 was carried out in negative FTMS mode with a
resolving power of 15,000.
Generation of a Quantitative Assay for DXA3
[14C]AA was oxidized using COX-1 as described for unla-
beled AA above. The amount of [14C]DXA3 was determined by
comparison with a [14C]AA standard curve analyzed using LC
separation with radiochemical detection (Berthold Technolo-
gies) using a Spherisorb ODS2 column (5 m, 150  4.6 mm;
Waters) with a gradient of 20–42.5% solvent B (acetonitrile,
0.1% formic acid) in solvent A (water, 0.1% formic acid) over 50
min, 42.5–90% solvent B from 50 to 60min, 90% solvent B from
ANew Bioactive Eicosanoid Generated by Human Platelets
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60 to 64.5min, 90 to 20% from 64.5 to 65.5min and 20% solvent
B from 65.5 to 75 min with a flow rate of 1 mlmin1, and
fractions were collected at 30-s intervals for LC/MS/MS confir-
mation of [14C]DXA3. The same gradient was also used for
LC/MS/MS detection of [14C]DXA3 (m/z 353.23 165.1).
Purification and Derivatization of DXA3 and GC/MS Analysis
DXA3 was purified from lipid extracts of thrombin-activated
platelets or COX-1 reactions using HPLC/UV on a Spherisorb
ODS2 column (5m, 150 4.6mm;Waters) with a gradient of
20–42.5% solvent B (acetonitrile, 0.1% formic acid) in solventA
(water, 0.1% formic acid) over 50min, 42.5–90% solvent B from
50 to 60min, 90% solvent B from 60 to 64.5min, 90 to 20% from
64.5 to 65.5 min, and 20% solvent B from 65.5 to 75 min with a
flow rate of 1mlmin1, and fractions collected at 30-s intervals.
DXA3-containing fractions were identified usingMS usingm/z
351.23 165.1, and then H2O was removed using Sep-Pak C18
cartridge purification (Waters). DXA3 was stored in methanol
at80 °C, prior to derivatization and GC/MS analysis.
2,3,4,5,6-Pentaflourobenzyl Bromide Derivatization of
Carboxyls—Lipid was dried underN2, and 25l of 1% 2,3,4,5,6-
pentaflourobenzyl bromide and 25 l ofN,N-diisopropylethyl-
amine, both in acetonitrile, were added. The mixture was vor-
texed and incubated for 30 min at 20 °C. The sample was dried
under N2.
Methyloxime Derivatization of Carbonyl Groups—Lipids
were dried under N2 in a glass vial. In a second vial, 1 ml of 1 N
NaOH was combined with a few grains of methyloxime. The
tubes were connected with the dry lipid in the uppermost tube
and solvent in the lower tube to separate and prevent solvation
and incubated for 2 h at 60 °C.
Trimethylsilane Derivatization of Hydroxyl Groups—Lipid
was dissolved in 50 l of N,O-bis(trimethylsilyl)trifluoroacet-
amide and 50 l of acetonitrile, vortexed, and incubated for 1 h
at 60 °C. The lipid was dried under N2, and 2ml of ethyl acetate
and 1ml of H2Owere added. The sample was vortexed, and the
ethyl acetate layer was recovered, dried, and then dissolved in
1:2H2O/methanol for LC/MS analysis or isooctane acetonitrile
for GC/MS. GC/MS was carried out on a DSQ Thermo Finni-
gan as follows: source temperature, 200 °C; reagent gas, meth-
ane; gas flow, 1.8 ml/min; negative polarity, full scan 50–600.
Column was a Phenomenex 30 M ZB-1.
Acid Hydrolysis of DXA3
Semi-purified DXA3 generated by COX-1 was solubilized in
acetonitrile (1ml) before addition of 1% acetic acid (4ml). Sam-
ples were left at room temperature for 30min before extraction
using a C18 solid phase extraction cartridge.
Tin(II) Chloride Reduction of DXA3
DXA3 generated via oxidation of 11-HPETE was reduced
using 95 g of SnCl2 in water for 10 min at room temperature.
Lipids were re-extracted as above using hexane/isopropyl/ace-
tic acid.
Statistics
Data on platelets are representative of at least three separate
donors, with samples run in triplicate for each experiment.
Data are expressed asmean S.E. of three separate determina-
tions. Statistical significance was assessed using an unpaired
two-tailed Student’s t test.Where the differences betweenmore
than two sets of data were analyzed, one-wayANOVAwas used
followed by Bonferroni multiple comparisons test, as indicated
in the figure legends. p  0.05 was considered statistically
significant.
Results
Platelets Generate DXA3—We initially sought to discover
esterified eicosanoids by scanning for precursors of m/z 351.2
in negative ion mode and of lipid extracts from thrombin-acti-
vated platelets. Thiswork is published as the characterization of
phospholipid esterified PGE2 and is described elsewhere (13).
During precursor scanning for 351.2, we uncovered an
unknown lipid also attached to phospholipids that was also
generated as a free acid. This is visible when analyzing free acid
lipids atm/z 351.2, where two lipids are seeded, including PGE2,
and amore prominent ion at 48min (marked by *, Fig. 1A) (13).
MS/MS demonstrated a complex spectrum with major ions at
m/z 163.2 and 165.2 that did not match any known eicosanoids
in the LipidMaps database (Fig. 1B). However, a number of ions
were indicative of prostaglandins, specifically m/z 333, 315,
289, and 271. The daughter ion at m/z 165.2 was then used to
selectively detect the lipid in multiple reaction monitoring
mode. A single lipid was visible at 48 min (Fig. 1C). The high
resolution m/z [M  H] of 351.2177 suggests an elemental
compositionC20H31O5, corresponding to arachidonic acid plus
three oxygen atoms, and the presence of 5 rings/double bonds
(Fig. 1B). Its elution on reverse phase LC/MS/MS, considerably
later than PGE2, indicated a less polar lipid (Fig. 1A).
Extensive structural characterization was undertaken using
GC/MS, derivatization, MS/MS, and MS3 and suggested the
lipid as DXA3. GC/MS presented in the supplemental material
and demonstrates one hydroxyl and no carbonyls (supplemen-
tal Fig. 1). For further structural confirmation, DXA3 or
DXA
3
-d8 generated by COX-1 was analyzed using high resolu-
tion MSn on an Orbitrap Elite, during LC elution. MS3 of
daughter ions atm/z 333.1 and 315.2 indicate the origin ofm/z
271.2 (Fig. 1,D–F), whereas MS3 ofm/z 225.1 and 207.1 shows
the origin ofm/z 163.1 (Fig. 2). Of note,m/z 155 is a prominent
ion generated on CID fragmentation of 8-HETE, thus support-
ing the position of the –OH group at C8. To further confirm,
analogous experiments were undertaken using deuterated AA
as substrate for DXA3 generation. MS3 of DXA3-d8 showed the
same fragmentation pattern; however, many ions showed an
additional ion at 1 atomicmass unit lower (e.g. m/z 340 and 321,
as well as the expected 341 and 322), supporting our proposed
fragmentationmechanisms as shown (supplemental Figs. 2 and
3). The lowerm/z ions represent ring opening with addition of
–H and concomitant loss of a single deuterium, as shown.
Finally, a UV spectrum was acquired during purification of low
nanogram amounts of COX-1-derived DXA3, showing a max
at 238 nm, similar to that reported for a similar DX by Teder et
al. (14). This confirms the presence of a UV chromophore and
is consistent with a conjugated diene at C12–15 of the lipid
backbone (Fig. 3, A and B).
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DXA3 is named based on the dioxolane structure, “A” for the
firstmember of the class discovered, and 3 for the number of dou-
ble bonds, as per traditional eicosanoid naming conventions (15).
Further work is required to confirm the structure usingNMR and
to determine enantiomeric/geometric isomer composition, using
synthetic standards once these become available.
DXA3 Activates Neutrophil Surface Integrin Expression—
Neutrophils incubated with purified DXA3 elevated surface
Mac-1 (integrin, CD11b/CD18), comparable with fMLP activa-
tion (Fig. 3, C and D). Together, fMLP and DXA3 caused an
additive effect on Mac-1 expression, suggesting they activate
neutrophils by distinct pathways (Fig. 3, C–F). However, at 10
nM, DXA3 effectively primed for fMLP activation after a 10min
pre-incubation (Fig. 3, G and H).
Human Platelets Acutely Generate DXA3 on Thrombin Acti-
vation via COX-1—As a purified standard is not yet available,
we synthesized and purified a biogenic standard by COX-1 oxi-
dation of [14C]AA oxidation in vitro, using COX-1. This was
quantified using radiochemical detection and HPLC-purified.
The radiolabeled standard was then utilized in LC/MS/MS
FIGURE 1.DXA3 is generated by human platelets, characterization usingMS/MS andMS
3 fragmentation. A, LC/MS/MS of DXA3 generated by thrombin-
activated platelets. LC/MS/MS separation of lipids from thrombin-activated (0.2 units/ml, 30 min) platelets, using m/z 351.2 3 351.1, as described in the
supplemental material, using a Q-Trap 4000. The later peak, labeled by (*), was identified as DXA3. B, MS/MS spectrum of DXA3. MS/MS of m/z 351.2 was
acquired at the apex of thepeak inAon anOrbitrap Elite.C, LC/MS/MSofDXA3. LC/MS/MSmonitoringm/z 351.23 163.1 demonstrated a single peak forDXA3.
D, LC/MS/MS of DXA3. Analysis was undertaken on theOrbitrap Elite in FTMSmode, separated by using reverse phase LC, isolated atm/z 351.2 in the Velos Pro,
then fragmentedbyusingCID at 50V,with resolution 15,000ppm, as describedunder “Experimental Procedures.” E, MS3 of daughter ion atm/z 333.2,withCID
at 30 V. C,MS3 of daughter ion atm/z 315.2, with CID 30 V. F,proposed fragmentation pathway form/z 351.2 generatingm/z 333.2071, which fragments tom/z
271.2067 via m/z 315.1967. DXA3 loses H2O forming 333.2071. Following ring opening, leaving a keto group at C9, H2O, and CO2 are lost, generating m/z
271.2067 via am/z 315.1967 intermediate, as shown.
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assays, to quantify cold DXA3 generated by COX-1, which was
then used as a primary standard for quantitation, against
PGE
2
-d4 as internal standard. Fig. 4, A–D, shows the
LC/MS/MS andMS/MS spectrumof purified [14C]DXA3 along
with standard curves for both radiochemical detection of
[14C]DXA3 and DXA3 versus PGE2-d4.
DXA3was undetectable basally with levels rising by 10min of
thrombin activation (n 7–10 separate donors, mean S.E.).
Levels were higher than PGE2, but lower than TXB2 or
12-HETE (a representative donor is shown in Fig. 4E, data for
all donors as Fig. 4F). Levels varied between genetically unre-
lated donors for all eicosanoids. DXA3 formed on activation by
collagen, ionophore, or collagen/thrombin of platelets, with
high levels already apparent 2 min post-activation (Fig. 5A). Its
thrombin-dependent formation was blocked by the selective
COX-1 inhibitor, SC560, aspirin, or indomethacin in vitro or in
vivo following administration of 75mg/day aspirin for 7 days in
healthy donors (Fig. 5, B–D). DXA3 was absent in thrombin-
activated platelets from a patient with genetic deficiency of
cPLA
2
(16) or in the presence of the cPLA2 inhibitor, cPLA2i
(Fig. 5, E and F). In contrast, neither iPLA2 nor sPLA2 appeared
significantly involved (data not shown). Pharmacological inhib-
itors/agonists implicated PAR-1 and -4 receptors, src-tyrosine
kinase, p38 MAPK, intracellular calcium, and PLC, but ruled
out phosphatidylinositol 3-kinase, although PKC played an
inhibitory role (Fig. 6, A–D). Murine platelets also generated
FIGURE2.CharacterizationofDXA3MS/MSandMS
3 fragmentation, usinghigh resolutionFTMS.A,MS3of daughter ion atm/z 207.1,withCID30V.B,MS3
of daughter ion at m/z 225.1, with CID 30 V. Bottom panel, proposed fragmentation pathway for m/z 351.2 generating m/z 333.2, then via fragmentation of
225.1, both at 207.1 and 163.1 are formed. Following ring opening, with keto group at C11, H2O is lost, followed by two 1[5]-sigmatropic shifts generatingm/z
333.2071 Following loss of a conjugated triene,m/z 225.1132 is generated, which then loses H2O, and via an intermediate fragments tom/z 207.1027 and last
163.1128.
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FIGURE 3. DXA3 contains a UV chromophore and primes and activates neutrophil integrin expression. A, DXA3 can be detected at 235 nm, during LC
elution. DXA3was generated using COX-1 as described under “Experimental Procedures” and then purified using LC/UV. B,DXA3 contains a UV chromophore.
A UV spectrum was acquired at the apex of the peak at 46.7 and shows a max at 238 nm. C, DXA3 activates neutrophil Mac-1 expression. Neutrophils were
incubated with fMLP, DXA3, or both, before addition of anti-human CD11b (Mac-1)-Alexa Fluor 647 and flow cytometry analysis as under “Experimental
Procedures.” A representative experiment repeated with three individual donors is shown (n  3, mean  S.E.). D–F, representative histograms depicting
increased Mac-1 expression following activation with fMLP, DXA3, or fMLP/DXA3. Line represents the Mac-1-positive neutrophil gate, as set using untreated
neutrophils. G, DXA3 primes neutrophil responses to fMLP. Bar chart showing activation of Mac-1 expression in three donors by fMLP with/without DXA3
priming for 10 min (n 3 mean S.E.). H, representative histogram showing increased fMLP-stimulated Mac-1 expression following priming by DXA3. Bar
represents theMac-1 positive neutrophil gate, as set using untreated neutrophils. Statistical significance usedMann-Whitney U test, ****, p 0.0001; ***, p
0.001; **, p 0.01. n 3 donors.
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DXA3 at levels similar to human cells; however, levels were
significantly higher in platelets genetically deficient in a second
arachidonate-oxidizing enzyme, 12-lipoxygenase (LOX) (Fig.
6E). Similarly, other COX-1-derived lipids were elevated in
these platelets, and 12-HETE-was absent (Fig. 6, F–H). Collec-
tively, these data show that thrombin-stimulated DXA3 gen-
eration depends on a highly coordinated signaling pathway,
culminating in cPLA2-dependent hydrolysis of AA from phos-
pholipids, prior to its oxygenation by COX-1 (Scheme 1).
Elucidating the Mechanism of DXA3 Generation by COX
Isoforms—To test whether DXA3 could be formed by COX
turnover, we examined the incubations of COX-1 or -2withAA
FIGURE 4. Setting up a quantitative assay for DXA3 and determining its levels in human platelets. [
14C]DXA3 was generated, using COX-1 and purified
using HPLC with radiochemical detection, as described in the supplemental material. [14C]DXA3 was quantified by comparing the radiochemical response to
[14C]AA.A, LC/MS/MS analysis ofm/z 353.23 165.1 showing [14C]DXA3 eluting at 49.51min, undertaken on the 4000Q-Trap as described under “Experimental
Procedures.” B,MS/MS spectrumof [14C]DXA3 showingm/z 353.2 as parent ion. Experiment was performed on the 4000Q-Trap platform in enhanced product
ion mode, as described under “Experimental Procedures.” C, standard curve for [14C]DXA3 using LC/MS/MS detection used for quantification of unlabeled
DXA3.D, standardcurve forquantitationofDXA3 inbiological samples. A standardcurvewasgeneratedwithvaryingDXA3but keepingPGE2-d4 levels constant,
and responses were plotted as shown. E, time course of eicosanoid generation by thrombin-activated platelets. Washed platelets were activated for varying
times, using 0.2 unitml1 thrombin, then lipids were extracted and analyzed using reverse phase LC/MS/MS, monitoring parent m/z 351.23 165.1 (DXA3),
319.23 179.1 (12-HETE),m/z 351.23 271.1 (PGE2), andm/z 369.23169.1 (TXB2), as described under “Experimental Procedures.” Data are representative of
experiments repeated three times on different donors (n 3, mean S.E.). F, levels of eicosanoids generated by genetically unrelated volunteers. Data are
shown as Tukey boxplots, where whiskers represent 1.5 the lower and upper interquartile range, data not included within the whiskers are displayed as an
outlier. Statistical significance used Mann-Whitney U test, ****, p 0.0001; ***, p 0.001; **, p 0.01. n 7–10 donors.
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FIGURE 5. Time course of agonist-stimulated generation and demonstrating the requirement for COX-1 and cPLA2 in DXA3 formation. A,
generation of DXA3 by human platelets. Washed platelets were activated for varying times, using 0.2 unitml
1 thrombin, 10 g/ml collagen, 10
mol/literA23187, and then lipids were extracted and analyzed using reverse phase LC/MS/MS, monitoring parent m/z 351.2 3 165.1 as described
under “Experimental Procedures.” Levels are expressed as analyte/internal standard. Data are representative of experiments repeated at least three
times on different donors (n 3, mean S.E.). B and C, requirement for COX-1 for DXA3 formation. Platelets were incubated with inhibitors 10 min prior
to thrombin activation (0.2 units/ml for 30 min at 37 °C). Lipids were extracted and analyzed using LC/MS/MS monitoring m/z 351.2 3 165.1, as
described under “Experimental Procedures.” Data are representative of experiments repeated at least three times on different donors (n 3, mean
S.E.). ***, p 0.001 versus thrombin, using ANOVA and Bonferroni post hoc test. Inhibitors usedwere aspirin, SC-560 (COX-1 selective), or indomethacin/
aspirin (non-selective COX inhibition). D, in vivo aspirin blocks platelet DXA3 generation. Lipids were analyzed following thrombin activation of washed
platelets, before or after supplementation with 75 mg/day aspirin for 7 days. Data are representative of five independent donors (n 5, mean S.E.);
***, p 0.001 versus thrombin alone, using ANOVA and Bonferroni post hoc test. E, cPLA2 is required for DXA3 formation. Platelets were incubated with
50 nM cPLA2 inhibitor (cPLA2i) 10 min prior to thrombin activation (0.2 units/ml for 30 min at 37 °C). Lipids were extracted and analyzed using LC/MS/MS
monitoringm/z 351.23 165.1, as described under “Experimental Procedures.” Data are representative of experiments repeated at least three times on
different donors (n  3, mean  S.E.). ***, p  0.001 versus thrombin, using ANOVA and Bonferroni post hoc test. F, platelets genetically deficient in
cPLA2 do not generate DXA3. Washed human platelets from a patient genetically deficient in cPLA2 or a healthy control were activated using thrombin
(0.2 units/ml for 30 min at 37 °C) before lipid extraction and analysis using reverse phase LC/MS/MS, monitoring m/z 351.23 165.1 as described under
“Experimental Procedures.”
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and also synthesized the free acid form of DXA3, through oxi-
dation of 11-HPETE, as described by Porter and co-workers for
generating cholesteryl-esterified dioxolane lipids (17, 18). In all
reactions, an ion with same retention time and MS/MS spec-
trum as the platelet lipid was formed (Fig. 7, A–H). However,
for either COX or 11-HPETE oxidation-generated DXA3, two
additional ions with m/z 351.23165.1 were seen eluting just
before and after DXA3, which may represent enantiomers or
positional isomers, e.g. at C8, C9, or C11. Monocyclic isomers
contain three chiral centers, thus eight possible stereoisomers
or four pairs of enantiomers): RRR, RRS, RSS, SSS, SSR, SRR,
SRS, and RSR (19). These additional ions show identical
MS/MS spectra to DXA3 (data not shown) suggesting these
peaks to be isomers. With enantiomers not being separated by
FIGURE 6. Demonstration of a coordinated signaling pathway leading to DXA3 formation in thrombin-activated platelets, its elevated formation in
murine platelets deficient in 12-LOX. A–C, effects of signaling inhibitors on DXA3 formation. A, PP2, 50 M (src family tyrosine kinase), p38 inhibitor, 100 nM
(p38MAPK), or U-73112, 5MPLC. B,wortmannin, 100 nM (PI 3-kinase), Gö 6850 (PKC), 100 nM (PKC), or vehicle (DMSO, 0.5%). C, EGTA 1mM (extracellular Ca2)
or 1,2-bis(2-aminophenoxy)ethane-N,N,N,N-tetraacetic acid tetrakis(acetoxymethyl ester) 10 M (intracellular Ca2). D, DXA3 is generated via PAR-1 and
PAR-4 receptor stimulation. Washed platelets were activated with a PAR-1 agonist, TFLLR-NH2 (20M), and/or a PAR-4 agonist, AY-NH2 (150M), for 30min at
37 °C and then analyzed as described under “Experimental Procedures.” ***, p 0.001 versus control, using ANOVA and Bonferroni post hoc test. E, generation
of DXA3 by murine platelets is enhanced in 12-LOX deficiency. Murine platelets were activated using 0.2 units/ml thrombin for 30 min before lipids were
extracted and analyzed using LC/MS/MS. F–H, generation of eicosanoids bymurine platelets. Murine platelets were activated using 0.2 units/ml thrombin for
30 min before lipids were extracted and analyzed using LC/MS/MS.
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our chromatography, up to four peaks of isomers would be
expected. The absence of these isomers in platelet extracts (Fig.
1C) indicates a higher degree of control over the cellular bio-
synthesis of DXA3, preventing generation of stereoisomers.
This may indicate that additional unknown enzymatic path-
ways exert control of DXA3 generation in platelets and will be
subject to further study.
Platelets generate significant amounts of 11-HETE via
COX-1 turnover (20, 21). This likely results from 11-hydroper-
oxyl radical intermediates (11-LOO) exiting the catalytic site,
then being reduced to form 11-HETE. Similarly, we reasoned
that DXA3 could form by COX via rearrangement of an
enzyme-generated intermediate exiting the active site early,
before full prostanoid ring formation. This could occur either at
the 11-LOO or 9,11-dioxolane radical stage (e.g. just before or
after formation of the DX ring). To examine this, we measured
DXA3 formation by two COX-2 mutants that generate more
11-HETE and less PGH2 than wild-type enzyme (22). Thus,
these enzymes favor escape of lipid radicals prior to DX/pros-
tanoid ring formation. Both mutants were found to generate
less DXA3, indicating that the DX ring forms before DXA3
leaves the active site (Fig. 8, A–C, and Scheme 2). Following
escape of a 9,11-DX radical, oxygen addition at C8 is expected,
followed by peroxidase-dependent reduction. This could be
mediated by COX-1 peroxidase or GSHperoxidase. In support,
DXA3 formationwas inhibited by 1–10mM iodoacetate, a thiol-
alkylating reagent (Fig. 8D).
Generation of DXA3 Is Independent of Thromboxane
Synthase—To determine the role of enzymatic activities down-
stream of COX-1, an inhibitor of thromboxane synthase was
added to platelets during activation. Picotamide led to inhibi-
tion of TXB2 generation and a corresponding elevation in
PGE2, because less PGH2 was being converted by thromboxane
synthase (Fig. 8, E and F). However, DXA3 formation was unaf-
fected (Fig. 8G). Last, there was no correlation between TXB2
andDXA3 levels, further supporting the idea that thromboxane
synthase is not involved in DXA3 generation (data not shown).
Generation of DXA3 by RAW 264 Cells and Human Serum—
To determine generation of DXA3 in other cell types, RAW264
macrophages were treated using LPS for 24 h, with/without
SCHEME 1. Summary of cellular synthesis pathway for free DXA3 by human platelets. Thrombin triggers platelet activation via PAR1 and PAR4 and then
intracellular signaling via Src tyrosine kinases,MEK,MAPK, PLC, and intracellular Ca2. Activation of cPLA2 leads to AA release, which is then oxidized via COX-1
forming DXA3. Free DXA3 is secreted to interact with neighboring cells, including neutrophils.
ANew Bioactive Eicosanoid Generated by Human Platelets
13458 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 26•JUNE 24, 2016
 at U
N
IV
 W
A
LES CO
LL O
F CA
RD
IF on June 28, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ionophore activation. Under basal conditions, these cells
express only COX-1, although following LPS treatment, they
up-regulateCOX-2.We found that cells required ionophore for
robust PG generation. DXA3 formation paralleled that of
PGD2, being present basally, but unaffected by inflammatory
activation. Thus, the lipid was most likely generated by COX-1
FIGURE7.DXA3 isgeneratedbypurifiedCOXsandviaoxidationof11-HPETE.A andB,COX isoformsgenerateDXA3. 3.5gof apo- or holo-COX-1orCOX-2,
or hematin (control for reconstituted enzyme), or DMSO (vehicle for hematin) was incubated with 150 M of AA for 3 min at 37 °C, before lipid extraction and
analysis as described under “Experimental Procedures.” Levels are expressed as ratio analyte to internal standard/3.5g of enzyme generated over 3min (n
3,mean S.E.). Data are representative of3 separate experiments. C andD, LC/MS/MS of DXA3 formed in vitro via COX-1 or -2. Lipid extracts were separated
using reversephase LC/MS/MS,monitoringm/z351.23165.1,with reactions asdescribedunder “Materials andMethods.” E, LC/MS/MSofDXA3 formed in vitro
via 11-HPETEoxidation. Purified11-HPETEwasoxidizedasdescribedunder “Experimental Procedures” and separatedusing LC/MS/MS. F andG,MS/MS spectra
of DXA3 formed in vitro via COX-1 or -2. Lipid extracts were separated as in C andD. MS spectra were acquired at the apex of elution of DXA3.H,MS/MS spectra
of DXA3 formed in vitro via 11-HPETE oxidation. Lipid extracts were separated as in C and D. MS spectra were acquired at the apex of elution of DXA3. * shows
position of additional isomers with identical MS/MS spectra to DXA3 eluting either before or after lipid.
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but not COX-2 in these cells (Fig. 9, A–D). Human blood was
harvested and allowed to clot. Analysis of serum demonstrated
a significant DXA3 peak, indicating that physiological coagula-
tion forms this lipid (Fig. 8E). In contrast, DXA3 was absent
from plasma (data not shown).
Discussion
Herein,weused a lipidomic approach to identify and character-
ize a new neutrophil-activating lipid, proposed to be DXA3,
formed endogenously by agonist-activated platelets in a COX-1-
dependent manner, by a macrophage cell line, and during blood
FIGURE8.DXA3exits theCOXactive sitedownstreamof11-LOO radical escape, althoughperoxidaseactivitybutnot thromboxanesynthase is involved in
plateletDXA3generation.A–C,COX-2mutants thatgeneratemore11-HETEformlessDXA3duringturnover.DXA3,PGE2,and11-HETEgeneratedbyCOX-2wild type
(WT) ormutants (V349A andW387F). Following reconstitutionwith hematin, 30M arachidonatewas oxidized using 10.2g of enzyme at 37 °C for 5min under O2
atmosphere.n 5–7, ***,p 0.05 (single factor ANOVA followedby two-tailed t test).D,peroxidase turnover is required forDXA3 generation. Plateletswere treated
with 1–10mM iodoacetate before thrombin activation and analysis of DXA3 using LC/MS as described under “Experimental Procedures.” One representative donor,
triplicates S.E., single factor ANOVA followed by Bonferroni ***, p 0.005 are shown. E–G, thromboxane synthase is not involved in platelet DXA3 generation.
Platelets were incubated with 50 M picotamide 10 min prior to thrombin activation (0.2 units/ml for 60 min at 37 °C). Lipids were extracted and analyzed using
LC/MS/MSmonitoringm/z 351.23 165.1, as described under “Experimental Procedures.” Data are representative of experiments repeated at least three times on
different donors (n 5,mean S.E.). ***, p 0.001 versus thrombin, using ANOVA and Bonferroni post hoc test.NS, not significant.
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clotting. At this time, we present a proposed structure based on
strong and consistent UV, GC/MS, and LC/MSn data. Once the
sufficient synthetic standard is available, full NMR analysis will be
undertaken. We note that many other biologically relevant lipids,
including thromboxane, leukotrienes, protectins, etc., were first pub-
lished as proposed structures in a similarmanner to our study.
SCHEME 2. Proposed mechanism of DXA3 formation by COX. During COX turnover, a dioxolane ring forms between C9 and C11, prior to prostanoid ring
formation, resulting in a carbon-centered radical at C8. Leakage of this lipid intermediate from the active site, then addition of oxygen followed by reduction
to LOOH, and then LOH leads to formation of DXA3.
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The mechanism of DXA3 formation in vitro by COX
enzymes is described, as well as its detailed cellular biosynthesis
pathway in human platelets. DXA3 represents the first DX eico-
sanoid isolated and characterized within cells. To date, these
have only been demonstrated to form via chemical oxidation of
purified arachidonate esters or 3 fatty acids or by in vitro
lipoxygenase oxidation of epoxides, and neither their genera-
tion by cells nor any bioactivities have been described (14, 18,
19, 24, 25, 27, 28). Our study greatly extends these old in vitro
observations by demonstrating that DX lipids are not only gen-
erated by live primary cells under physiological conditions, but
they possess biological activity of relevance to innate immunity.
This study places this eicosanoid in a new family of products
likely relevant as a lipid mediator as are the prostaglandins,
leukotrienes, and P450-derived eicosanoids. Extending these
cell biology studies to in vivomeasurements of leukocyte func-
tion and inflammation will be undertaken as soon as the syn-
thetic standard becomes available.
Eicosanoids are essential lipid signaling mediators involved
in diverse biological processes (29–32). Identification of new
FIGURE9.DXA3 isgeneratedbyRAWcells andduringphysiological coagulation.A–D,RAWcells generateDXA3under basal non-inflammatory conditions.
RAWcellswere incubated in serum-freeDMEMfor 1hat 37 °C, 5%CO2.Whereused, 200ng/ml LPSwas added for 24h. Cells (810
6ml1)were activatedusing
10 M A23187 at 37 °C for 10 min, and lipids were extracted and analyzed using LC/MS/MS. DXA3 was monitored usingm/z 351.2 to 165.1 and PGE2/D2 using
m/z 351.2 to 271.1 utilizing a 4000 QTrap. A and B, LC/MS/MS of basal RAW cells with/without 10 M A23187. C and D. LC/MS/MS of LPS-treated RAW cells
with/without 10MA23187. E,DXA3 is generated during physiological blood clotting.Whole bloodwas clotted, serumwas harvested, and lipidwas extracted
as described under “Experimental Procedures.” LC/MS/MS was performed as for free DXA3 on a Q-Trap platform. Note that retention time of serum and RAW
cell DXA3differs slightly because thesewere analyzed severalmonths apart on different columns. The identities have been confirmed through co-elutionwith
platelet DXA3 (data not shown).
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bioactive eicosanoids from this pathway could pave the way for
additional and more selective therapeutic approaches. Thus,
the proposed structure for DXA3 represents a new member of
this family, characterized by a unique five-membered endoper-
oxide ring, and generated by a COX isoform known to play
important roles in vascular disease and, more recently, in
cancer.
Mac-1 (CD11b/CD18) is the predominant 2 integrin on
neutrophils that mediates adhesion-dependent processes, such
as binding to the endothelium or phagocytosis, recruitment,
and transendothelial migration (33, 34). Herein, we show that
DXA3 enhances Mac-1 on the cell surface (Fig. 3). The only
other known Mac-1-inducing eicosanoids are leukotriene B4
and 5-oxo-ETE, both neutrophil-derived lipids (35, 36). Thus,
neutrophil integrin activation by platelet-derived DXs could be
of relevance during acute inflammation and infection. DXA3
was generated by platelets utilizing endogenous substrate in
nanogramamounts that are	10-fold higher thanplatelet PGE2
(Fig. 4E). Its formation does not require supply of exogenous
substrates and can be triggered directly by pathophysiological
agonists in healthy primary cells, both important criteria in
establishing that a new lipidmediator is endogenously relevant.
As DXA3 was generated via COX-1 in platelets, we reasoned
that it could form through two potential mechanisms, either (i)
rearrangement of 11-LOO, known to be released by the
enzyme during turnover, or (ii) that the dioxolane ring could
form before the lipid exits from the active site (20, 21, 23, 37). In
both cases, attack at C9 by the peroxyl radical would form the
9,11-dioxolane, which would be followed by oxygen addition at
C8, and finally peroxidase reduction of the resulting LOOH by
COX-1 peroxidase or GSH peroxidase in platelets. Our data
using mutant COX-2 enzymes that generate less DXA3 but
more 11-HETE suggest that the DX ring forms before lipid
release by the enzyme. Thus, dioxolane ring formation occurs
first and before prostanoid ring closure between C8 and C12
(Scheme 2). Finally, given that COX-1 generates 11R-HETE,we
postulate that the dioxolane ring will likely be 9S,11R. Our
observation of a single DX isomer in platelets but several in
purified enzyme reactions indicates that platelets exert addi-
tional control over its biosynthesis. This may be at the stage of
oxygen insertion into the chiral center at C8.
DXA3 was generated by platelets via a highly coordinated
sequence of signaling events, including PAR-1 and -4, src tyro-
sine kinases, intracellular Ca2, cPLA2, PLC, p38, and MAPK.
This indicates tight control of its formation, similar to genera-
tion of other COX metabolites, such as TXA2. The signaling
pathway is distinct from generation of free and esterified HETE
and hydroxydocosahexadienoic acids, which form via 12-LOX,
and require extracellular calcium, independent of PLC and
MAPK (6, 26).
DXA3 was also generated by RAW cells as a single isomer,
similar to platelets. Our preliminary data suggest that it origi-
nates primarily from COX-1 in these cells. In contrast, we
found that either isoform could generate the lipid in vitro. In
line with our observation that cellular DXA3 is a single isomer
in platelets and RAW cells, although three isomers form via
COXs in vitro, this collectively suggests that cellular DXA3 gen-
eration is under enzymatic control downstream of its synthesis
by COX-1. Future studies will examine the ability of cellular
COX-2 to generate the isoform and under which activation
conditions. COX-1 is important not only in acute innate immu-
nity but also in gastric function and development, and thus its
generation by this isoform may have wider implications for
eicosanoid biology in other organs.
Murine platelets also generatedDXA3, and levels of this were
enhanced in cells deficient in 12-lipoxygenase. This may be
related to greater availability of substrate, although this has not
been explored herein.
Eicosanoids include a large number of related structures
formed via oxidation of arachidonate, following its release from
intracellular membranes by phospholipases. A rapid burst of
eicosanoid generation is a key event during cell activation and is
stimulated during innate immunity by bacterial products,
growth factors, cytokines, thrombin, and collagen.Most known
eicosanoids from COXs were identified and structurally char-
acterized in the 1980–1990s and include platelet-derived lipids,
TXA2 and 12-HETE, as well as the PGs, exemplified by PGE2,
and D2, well known as mediators of pain, fever, cell prolifera-
tion, and innate and adaptive immune responses. Our observa-
tion of a cellularly generated DX eicosanoid defines a new class
of these lipids formed endogenously bymammalian cells. More
members of this class are possible, given recent observations of
purified LOXs being able to generate DX isomers via oxidation
of epoxides in vitro in acellular experiments (14).
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Supplementary Data. 
 
 
Supplementary Results 
 
Derivatization, acid hydrolysis and catalytic hydrogenation of DXA3 
DXA3 generated by COX-1 oxidation of AA was partially purified using reverse phase 
HPLC, as described in Supplementary Methods, derivatized using PFB, MOX and/or 
TMS, and analyzed using GC/MS and/or LC/MS. First, LC/MS of MOX-derivatized DXA3 
showed no loss of lipid, indicating that it does not contain any carbonyl groups 
(Supplementary Figure 1 A,B). In contrast, a small amount of contaminating PGE2 was 
lost on derivatization. It was not possible to analyze TMS-ethers using LC/MS/MS due 
to derivatization of the carboxyl group by the reagent (required for PFB derivatization 
and negative ionization and detection). Derivatization of DXA3 using PFB, then MOX 
and TMS followed by GC/MS analysis, yielded signals at m/z 423 (+TMS), indicating 
one hydroxyl (Supplementary Figure 1 C). Note that during negative ion chemical 
ionization (NICI) analysis, the PFB group is lost generating the carboxylate anion, which 
is detected as a negative signal. Also, several lipids are detected on derivatization since 
three isomers as generated by COX-1 (Figure 7 C).  Ions were not detected for addition 
of carbonyls or more than one hydroxyl (not shown). The MS spectrum at 11.4 min 
shows a molecular ion of m/z 423.2 and a fragment at m/z 333.1 (-90 amu), 
representing the loss of –OTMS (Supplementary Figure 1 D). This further supports the 
presence of a single hydroxyl group.  Since the remaining two oxygens are neither 
hydroxyl or carbonyl, this is consistent with the proposed dioxolane structure.  Epoxides, 
but not dioxolanes are acid sensitive. Thus, purified DXA3 was incubated with 1% acetic 
acid, and analyzed using LC/MS. No loss of m/z 351 was observed (Supplementary 
Figure 1 E,F). We note that DXA3 will be considerably more lipophilic than PGE2 or D2, 
which both contain additional hydroxyl and carbonyl functional groups, consistent with 
our observation of later elution on reverse phase HPLC (Figure 1 A).  
 
Supplementary Figure Legends. 
 
Supplementary Figure 1. Derivatization and analysis of DXA3 using LC/MS/MS and 
GC/MS, shows the presence of one hydroxyl and no carbonyl or epoxide 
functional groups. Panels A,B. LC/MS shows DXA3 contains no carbonyl groups. 
Semi-purified DXA3 generated using COX-1 was derivatized using methyloxime (MOX) 
and analyzed using LC/MS/MS, on the 2000 Q-Trap, monitoring m/z 351 in Q1. Panel 
A, no derivatization. Panel B, after derivatization. Note: loss of small peak 
corresponding to contaminating PGE2 in this preparation confirms derivatization has 
been successful.  Panels C,D. GC/MS shows that DXA3 contains one hydroxyl group 
and no carbonyls.  Purified DXA3 generated using COX-1 was derivatized using PFB, 
MOX and TMS, and analyzed using GC/MS as described in Methods. Panel C. m/z of 
derivative with one hydroxyl, showing a major peak at 11.38 min, and two additional 
smaller peaks at either side. Panel D. MS spectrum at 11.38 shows ion at m/z 432, with 
loss of 90 amu at m/z 333 (-OTMS).  Panels E,F. DXA3 is insensitive to acid hydrolysis 
indicating no epoxide groups.  Semi-purified DXA3 generated by COX-1 was solubilized 
in acetonitrile before the addition of 1 % acetic acid (1:4). Following 30 min at 22 °C, 
lipids were extracted using a C18 Bond Elute cartridge and analyzed using LC/MS/MS 
on the 2000 Q-Trap for m/z 351.2 in full scan Q1 mode. Panel E: no hydrolysis, Panel F: 
after hydrolysis. 
 
Supplementary Figure 2. Characterization of DXA3-d8 MS/MS and MS3 
fragmentation, using high resolution FTMS. Panel A. LC/MS/MS of COX-1 derived 
DXA3-d8, generated using AA-d8 as substrate. Analysis was undertaken on the Orbitrap 
Elite in FTMS mode, separating using reverse phase LC, isolating m/z 359.27 in the 
Velos Pro, then fragmenting using CID at 50 V, with resolution 15,000 ppm, as 
described in Methods.   Panel B. MS3 of daughter ion at m/z 340.25 (smaller ion 
adjacent to m/z 341 in Panel a), with CID 30V. Panel C. MS3 of daughter ion at m/z 
322.24, with CID of daughter ion at 30V. Panel d. Proposed fragmentation pathway for 
m/z 359.2679 generating m/z 341.2573, which fragments to m/z 278.2507 via via m/z 
322.2405.  DXA3 loses H2O forming m/z 341.2573. Following ring opening m/z 
340.2511 , leaving a keto group at C9, H2O and CO2 are lost, generating m/z 
278.2507via a m/z 322.2405 intermediate, as shown. 
 
Supplementary Figure 3. Characterization of DXA3-d8 MS/MS and MS3 
fragmentation, using high resolution FTMS.  Panel A. MS3 of daughter ion at m/z 
231.15 with CID 30V.  Panel B. MS3 of daughter ion at m/z 212.13, with CID 30V. Panel 
c. Proposed fragmentation pathway for m/z 359.2 generating m/z 358.2, then via 
fragmentation of 340.2, forming 212.1 and 168.1. Following ring opening, with keto 
group at C11, H2O is lost, followed by two 1[5]-sigmatropic shifts generating m/z 
340.2511. Following loss of a conjugated triene, m/z 231.1509 is generated, which then 
loses H2O, and via an intermediate fragments to m/z 212.1341 and last 168.1422.   
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